Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Return on Capital Employed (2019 - 2025)

Inmune Bio's Return on Capital Employed history spans 7 years, with the latest figure at 1.82% for Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 75.0% year-over-year to 1.82%; the TTM value through Sep 2025 reached 1.82%, down 75.0%, while the annual FY2024 figure was 1.04%, 45.0% down from the prior year.
  • Return on Capital Employed for Q3 2025 was 1.82% at Inmune Bio, up from 1.93% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.23% in Q1 2021 and bottomed at 1.93% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 0.44% (2023), against an average of 0.73%.
  • The largest annual shift saw Return on Capital Employed increased 9bps in 2021 before it plummeted -84bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.29% in 2021, then decreased by -23bps to 0.36% in 2022, then plummeted by -99bps to 0.72% in 2023, then plummeted by -52bps to 1.09% in 2024, then plummeted by -67bps to 1.82% in 2025.
  • Per Business Quant, the three most recent readings for INMB's Return on Capital Employed are 1.82% (Q3 2025), 1.93% (Q2 2025), and 1.35% (Q1 2025).